Development of Camera Based Gait Quality Measure for Persons With Multiple Sclerosis

Launched by SHIRLEY RYAN ABILITYLAB · Jul 18, 2024

Keywords

ClinConnect Summary

This clinical trial is focused on developing a new way to measure how well people with Multiple Sclerosis (MS) walk, called the Gait Deviation Index (GDI). The goal is to better understand and assess walking quality in individuals who have different forms of MS, including those with relapsing-remitting and secondary progressive MS. The study is currently looking for participants aged between 18 and 75 who can walk on their own and have been relapse-free for at least a month. If you are taking a specific medication called dalfampridine, you may still be eligible as long as you have been on the same dose for at least two months.

If you decide to participate, you’ll be part of a process that aims to improve how we measure walking in people with MS, which could ultimately help in developing better treatments. Participants will be evaluated to ensure they meet the necessary health criteria, and they can expect to engage in activities related to walking assessments. It's important to note that individuals with recent injuries or surgeries affecting their ability to walk may not be eligible. This study is a great opportunity to contribute to knowledge that could benefit others living with MS.

Gender

ALL

Eligibility criteria

• Inclusion criteria:
• • Diagnosis of relapsing form of MS (including relapsing-remitting MS and secondary progressive MS)
• • Able to ambulate overground
• • Relapse free for at least 1 month
• • Age ≥18 and ≤ 75 years
• • Participants using dalfampridine will be eligible if taking the same daily dose for at least 2 months prior to screening
• Exclusion criteria:
• • - Orthopedic injuries, fractures, surgeries or other conditions affecting locomotor function or weight bearing